详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen

147| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin 300121, China. [2]School of Medicine, Nankai University, Tianjin, China. [3]Tianjin Institute of Coloproctology, Tianjin, China. [4]School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China. [5]The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China. [6]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [7]The Third Central, Clinical College of Tianjin Medical University, Tianjin, China. [8]Department of Agriculture Insect, Institute of Plant Protection, Tianjin Academy of Agricultural Sciences, Tianjin, China

出处：

DOI：

ISSN：

摘要：

We evaluate the prognostic value of chemotherapy and other prognostic factors on overall survival among colon patients with deficient mismatch repair (dMMR), and determine the optimum time to start chemotherapy after surgery. Data of 306 colon cancer patients with dMMR who received radical surgery were collected from three Chinese centers between August 2012 and January 2018. Overall survival (OS) was assessed with the Kaplan-Meier method and log-rank. Cox regression analysis were used to assess influencing prognosis factors. The median follow-up time for all patients was 45.0 months (range, 1.0-100). There was a nonsignificant OS benefit from chemotherapy for patients with stage I and stage II disease, including high-risk stage II disease (log-rank p: 0.386, 0.779, 0.921), and a significant OS benefit for patients with stage III and stage IV disease for receiving post-operation chemotherapy (log-rank p = 0.002, 0.019). Stage III patients benefitted from chemotherapy regimens that contained oxaliplatin (log-rank p = 0.004), and Starting chemotherapy with oxaliplatin treatment earlier resulted in better outcomes (95% CI 0.013-0.857; p = 0.035). Chemotherapy regimens containing oxaliplatin can prolong the survival time of stage III and IV dMMR colon cancer patients. This beneficial manifestation was more pronounced after starting chemotherapy treatment early post operation. High risk stage II dMMR colon patients including T4N0M0 cannot benefit from chemotherapy.© 2023. The Author(s).

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

最新[2025]版：

大类 | 3 区综合性期刊

小类 | 3 区综合性期刊

JCR分区：

出版当年[2021]版：

Q2 MULTIDISCIPLINARY SCIENCES

最新[2024]版：

Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 3.9 最新[2024版] 4.3 最新五年平均 4.997 出版当年[2021版] 5.516 出版当年五年平均 4.38 出版前一年[2020版] 4.6 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin 300121, China. [2]School of Medicine, Nankai University, Tianjin, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin 300121, China. [3]Tianjin Institute of Coloproctology, Tianjin, China. [5]The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：